CDK4 and renal cell carcinoma: To investigate whether the action of ribociclib in RCC cells is associated with its ability to inhibit the CDK4/6-cyclin D-Rb pathway, we firstly determined the level of Rb phosphorylation in multiple RCC cell lines that are both sensitive and resistant to ribociclib.